Description: Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is based in La Jolla, California.
Home Page: ensysce.com
7946 Ivanhoe Avenue
La Jolla,
CA
92037
United States
Phone:
858-263-4196
Officers
| Name | Title |
|---|---|
| Dr. D. Lynn Kirkpatrick | CEO & Director |
| Mr. David C. Humphrey | Chief Financial Officer |
| Dr. Jeffrey Millard | Chief Operating Officer |
| Mr. Richard Wright M.B.A., MSE | Chief Bus. Officer |
| Mr. Geoff Birkett | Chief Commercial Officer |
| Dr. William K. Schmidt | Chief Medical Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |